Single-Dose Pharmacokinetics of the CCR9 Receptor Antagonist Vercirnon in Healthy US and Japanese Subjects.

Haberer, Lynda J; Hacquoil, Kimberley; Ino, Hiroko; Sakamoto, Takashi; Kanemoto, Noriaki; McSherry, Iain; Hirama, Toshiyasu

Haberer, Lynda J; Hacquoil, Kimberley; Ino, Hiroko; Sakamoto, Takashi; Kanemoto, Noriaki; McSherry, Iain; Hirama, Toshiyasu.

Afiliação

Haberer LJ; Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC, USA.
Hacquoil K; Clinical Statistics, Quantitative Sciences, GlaxoSmithKline, Stevenage, UK.
Ino H; Clinical Pharmacology Department, Development and Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan.
Sakamoto T; Clinical Pharmacology Department, Development and Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan.
Kanemoto N; Portfolio Management Office, GlaxoSmithKline K.K., Tokyo, Japan.
McSherry I; Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Stockley Park, UK.
Hirama T; Clinical Pharmacology Department, Development and Medical Affairs Division, GlaxoSmithKline K.K., Tokyo, Japan.

Clin Pharmacol Drug Dev ; 2(4): 387-93, 2013 Oct.

Article em En | MEDLINE | ID: mdl-27121943

Palavras-chave

CCR9 receptor antagonist; Crohn's disease; bioavailability; pharmacokinetics; vercirnon

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Clin Pharmacol Drug Dev Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google